Treatment with L-4F, in the absence or presence of pravastatin, effectively reduced manifestations of lupus-like autoantibody production, glomerulonephritis, and osteopenia in our apoE-/-Fas-/- B6 murine model of accelerated atherosclerosis in SLE. Here, APOE is linked to glomerulonephritis.